Emmaus Life Sciences, Inc. 8-K

What Happened Emmaus Life Sciences, Inc. (EMMA) filed an 8-K on April 17, 2026 reporting that, by written consent on April 16, 2026, its Board appointed Henry H. Du to fill the vacancy created by the resignation of director Jon Kuwahara. Mr. Du, age 48, is expected to replace Mr. Kuwahara as the sole member of the Board’s Audit Committee. He has served as Vice President – Finance & Accounting and interim Chief Financial Officer of Alpha Cognition, Inc. (NASDAQ: ACOG) since October 2024 and previously held senior finance and accounting roles at other life sciences companies. Mr. Du is a Certified Public Accountant and holds a B.A. from Claremont McKenna College.

Key Details

• Appointment effective by written consent: April 16, 2026.
• Replaced director: Jon Kuwahara; Mr. Du is expected to be sole Audit Committee member.
• Background: Interim CFO and VP Finance & Accounting at Alpha Cognition (since Oct 2024); CPA.
• Compensation & conflicts: Expected to receive the same director compensation as other directors; no family relationships or reportable related-party transactions disclosed.

Why It Matters This filing updates investors on a governance change: a new director with a finance and accounting background (including CPA and interim CFO experience) will join the board and lead the Audit Committee. That is directly relevant to financial oversight and internal control governance. The company disclosed no related-party transactions and said Mr. Du will be paid the same as other directors, so there are no additional compensation or conflict details disclosed in this 8-K. Investors tracking board composition, audit oversight, or corporate governance at Emmaus should note this personnel change and watch for any future filings with additional committee or compensation details.